Given the limited treatment options for patients with advanced HER2-positive (HER2+) solid tumors, recent regulatory approvals in the US and Europe have brought hope for many individuals in this patient population. The anticipated expansion of potential approvals in other regions globally underscores the need for clinicians worldwide to understand the importance of integrating routine molecular profiling into clinical practice to identify actionable biomarkers and tailor therapy accordingly. Other clinical protocols that would ensure accurate treatment selection include effective utilization of molecular tumor boards, which would enhance collaboration among the multidisciplinary team and lead to optimal patient outcomes. In this broadcast, expert faculty will review the most recent data supporting the use of HER2-directed therapies, how to use molecular profiling to identify patients for whom these treatments are appropriate, and best practices for collaboration among the multidisciplinary team.
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
Join our expert faculty as they explore the importance of molecular profiling when developing treatment regimens for patients with HER2+ tumors.
United States
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Eric Van Cutsem, MD, PhD
Division Head, Digestive Oncology
University Hospitals Gasthuisberg
University of Leuven
Leuven, BelgiumNo relevant financial relationships have been reported at this time.
Faculty:
David SP Tan, MBBS, PhD, PRCP
Associate Professor
National University Cancer Institute
SingaporeNo relevant financial relationships have been reported at this time.
James Chih-Hsin Yang, MD, PhD
Lab Supervisor
National Taiwan University
Taipei City, TaiwanNo relevant financial relationships have been reported at this time.
Kathleen N. Moore, MD, MS, FASCO
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma
Oklahoma, USANo relevant financial relationships have been reported at this time.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the role of molecular profiling to guide HER2-positive tumor-agnostic treatment selection in advanced solid tumors
- Incorporate molecular profiling in all patients to ensure assessment for HER2-positivity in patients with advanced solid tumors
- Analyze the impact of a molecular tumor board on patients with HER2-positive advanced solid tumors
- Develop evidence- and guideline-based strategies for patient selection and sequencing of therapies in HER2-positive advanced solid tumors
- Integrate a multidisciplinary team-based approach to adverse event monitoring, prophylaxis, and management in patients with HER2-positive advanced solid tumors
Target Audience
This activity has been designed to meet the educational needs of oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with solid tumors.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
Given the limited treatment options for patients with advanced HER2-positive (HER2+) solid tumors, recent regulatory approvals in the US and Europe have brought hope for many individuals in this patient population. The anticipated expansion of potential approvals in other regions globally underscores the need for clinicians worldwide to understand the importance of integrating routine molecular profiling into clinical practice to identify actionable biomarkers and tailor therapy accordingly. Other clinical protocols that would ensure accurate treatment selection include effective utilization of molecular tumor boards, which would enhance collaboration among the multidisciplinary team and lead to optimal patient outcomes. In this broadcast, expert faculty will review the most recent data supporting the use of HER2-directed therapies, how to use molecular profiling to identify patients for whom these treatments are appropriate, and best practices for collaboration among the multidisciplinary team.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Eric Van Cutsem, MD, PhD
Division Head, Digestive Oncology
University Hospitals Gasthuisberg
University of Leuven
Leuven, BelgiumNo relevant financial relationships have been reported at this time.
Faculty:
David SP Tan, MBBS, PhD, PRCP
Associate Professor
National University Cancer Institute
SingaporeNo relevant financial relationships have been reported at this time.
James Chih-Hsin Yang, MD, PhD
Lab Supervisor
National Taiwan University
Taipei City, TaiwanNo relevant financial relationships have been reported at this time.
Kathleen N. Moore, MD, MS, FASCO
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma
Oklahoma, USANo relevant financial relationships have been reported at this time.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the role of molecular profiling to guide HER2-positive tumor-agnostic treatment selection in advanced solid tumors
- Incorporate molecular profiling in all patients to ensure assessment for HER2-positivity in patients with advanced solid tumors
- Analyze the impact of a molecular tumor board on patients with HER2-positive advanced solid tumors
- Develop evidence- and guideline-based strategies for patient selection and sequencing of therapies in HER2-positive advanced solid tumors
- Integrate a multidisciplinary team-based approach to adverse event monitoring, prophylaxis, and management in patients with HER2-positive advanced solid tumors
Target Audience
This activity has been designed to meet the educational needs of oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with solid tumors.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0.25 credits
Joyce O'Shaughnessy, MD
0.25 creditsDifferentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program creditsHope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
1.25 program creditsEndpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
1.25 program creditsHope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
1.25 program credits